<DOC>
	<DOC>NCT00946153</DOC>
	<brief_summary>The purpose of this study is to determine maximum tolerated dose (MTD), efficacy, safety and tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor effect of E7080 when is administered continually once daily in patients with advanced hepatocellular carcinoma.</brief_summary>
	<brief_title>Study of E7080 in Patients With Advanced Hepatocellular Carcinoma (HCC)</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<mesh_term>Lenvatinib</mesh_term>
	<criteria>Inclusion criteria: 1. Histologically or clinically confirmed diagnosis of advanced HCC 2. Eastern Cooperative Oncology GroupPerformance Status (ECOGPS): 01 3. Adequate laboratory values/organ function tests Exclusion criteria: 1. Simultaneous or metachronous cancers 2. Pericardial, ascites, or pleural effusion requiring drainage 3. Brain metastasis/meningeal carcinomatosis presenting clinical symptoms or requiring treatment 4. Malabsorption syndrome 5. Arteryportal vein shunt or arteryvein shunt preventing proper diagnosis of tumor 6. Use of drugs known to inhibit cytochrome P3A4</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Carcinoma</keyword>
	<keyword>Hepatocellular</keyword>
</DOC>